Cargando…
A COVID‐19 human viral challenge model. Learning from experience
The controlled human infection model and specifically the human viral challenge model are not dissimilar to standard clinical trials while adding another layer of complexity and safety considerations. The models deliberately infect volunteers, with an infectious challenge agent to determine the effe...
Autores principales: | Lambkin‐Williams, Rob, DeVincenzo, John P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578316/ https://www.ncbi.nlm.nih.gov/pubmed/32790065 http://dx.doi.org/10.1111/irv.12797 |
Ejemplares similares
-
Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis
por: Pickles, Raymond J, et al.
Publicado: (2015) -
The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics
por: Lambkin-Williams, Rob, et al.
Publicado: (2018) -
902. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of a Single Immunization of Ad26.RSV.preF against RSV Infection in a Viral Challenge Model in Healthy Adults
por: DeVincenzo, John, et al.
Publicado: (2019) -
The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process
por: Catchpole, Andrew P., et al.
Publicado: (2018) -
Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study
por: Sadoff, Jerald, et al.
Publicado: (2021)